New Risk • Jun 24
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m). Ankündigung • Jun 05
Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance Committee Bioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting. New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Recent Insider Transactions • Mar 24
CEO, MD & Executive Director recently bought AU$90k worth of stock On the 19th of March, Samuel Watson bought around 2m shares on-market at roughly AU$0.05 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Samuel's only on-market trade for the last 12 months. New Risk • Feb 27
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 87% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Market cap is less than US$100m (AU$134.4m market cap, or US$95.6m). Ankündigung • Feb 13
Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026 Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026 Ankündigung • Dec 16
Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 115,600,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,400,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Ankündigung • Oct 28
Bioxyne Limited, Annual General Meeting, Nov 26, 2025 Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 Australia Reported Earnings • Oct 05
Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024) Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$29.3m (up 204% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 17% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024) Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$30.4m (up 216% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jul 23
Bioxyne Limited to Report Q4, 2025 Results on Jul 28, 2025 Bioxyne Limited announced that they will report Q4, 2025 results on Jul 28, 2025 Buy Or Sell Opportunity • May 07
Now 29% overvalued Over the last 90 days, the stock has fallen 33% to AU$0.026. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Apr 15
Now 21% overvalued Over the last 90 days, the stock has fallen 14% to AU$0.025. The fair value is estimated to be AU$0.021, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Ankündigung • Apr 03
Bioxyne Limited Appoints Michael Barnes to Its Advisory Board Bioxyne Limited (BXN) announced that leading consultant neurologist, Professor Michael Barnes MD. FRCP ("Mike" or "Prof Barnes"), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board. Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK. Prof Barnes was previously an advisor to GW Pharmaceuticals. The Company will also leverage Prof Barnes's experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways. Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness,
education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth.
In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley. Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life- changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council. As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry. As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the
Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries. Ankündigung • Mar 21
Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 115,600,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,400,000
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Buy Or Sell Opportunity • Mar 14
Now 35% overvalued after recent price rise Over the last 90 days, the stock has risen 42% to AU$0.027. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Ankündigung • Jan 23
Bioxyne Limited Upgrades Revenue Guidance for the Year Ended 30 June 2025 Bioxyne Limited advised that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to $25,000,000. Ankündigung • Oct 04
Bioxyne Limited, Annual General Meeting, Nov 21, 2024 Bioxyne Limited, Annual General Meeting, Nov 21, 2024. Reported Earnings • Oct 02
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023) Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023) Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.66m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 23
Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million. Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 145,000,000
Price\Range: AUD 0.01
Transaction Features: Subsequent Direct Listing Ankündigung • Apr 18
Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million. Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 145,000,000
Price\Range: AUD 0.01
Transaction Features: Subsequent Direct Listing New Risk • Apr 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Market cap is less than US$10m (AU$15.2m market cap, or US$9.86m). Ankündigung • Nov 17
Bioxyne Limited Announces Retirement of N H Chua as Director Bioxyne Limited announced that Mr. N H Chua has retired from the Board following the Annual General Meeting that was held 17 November 2023. Sam Watson will continue as sole Chief Executive Officer and Managing Director. Ankündigung • Oct 05
Bioxyne Limited, Annual General Meeting, Nov 17, 2023 Bioxyne Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time. Reported Earnings • Oct 05
Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022) Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$5.30m (up AU$4.84m from FY 2022). Net loss: AU$1.94m (loss widened 293% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 01
Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022) Full year 2023 results: EPS: AU$0.002. Revenue: AU$5.34m (up 115% from FY 2022). Net loss: AU$1.94m (loss widened AU$1.70m from FY 2022). New Risk • Aug 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$2.3m revenue, or US$1.5m). Market cap is less than US$100m (AU$22.8m market cap, or US$14.6m). Ankündigung • May 24
Bioxyne Limited Appoints Jason Hine as Director Bioxyne Limited announced that the appointment of Jason Hine as director of the company with effect from May 19, 2023. Ankündigung • May 23
Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd. Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. On March 20, 2023, Bioxyne executed the long form Sale and Purchase Agreement with BLS’ majority shareholders. Completed due diligence confirms the synergies between the Bioxyne and BLS. The Bioxyne and BLS have commenced formulating a combined business development growth strategy for post-acquisition. Other conditions precedent to completion include, The remaining minority BLS shareholders acceding as parties to the SPA, New employment agreements for key BLS employees, including appropriate restraints and No material adverse change occurring in relation to Breathe Life Sciences. BXN and BLS will work together, in good faith, to satisfy the remaining conditions precedent by May 31, 2023 to implement the proposed transaction. If the conditions precedent are not satisfied (or waived) by this date, then unless the Long Stop Date is extended by agreement, either party may terminate the SPA and the proposed transaction. As of May 5, 2023, Bioxyne received shareholder approval for the acquisition of BLS.Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd on May 22, 2022. Bioxyne has completed the acquisition of Breathe Life Sciences following shareholder approval, due diligence and the satisfaction of all conditions precedent. BLS's Sam Watson (Chief Executive Officer) and Jason Hine (Chief Operating Officer) will be appointed to the Board of Directors. Reported Earnings • Feb 24
First half 2023 earnings released First half 2023 results: Revenue: AU$1.28m (down 9.9% from 1H 2022). Net income: AU$23.2k (up 409% from 1H 2022). Profit margin: 1.8% (up from 0.3% in 1H 2022). The increase in margin was driven by lower expenses. Ankündigung • Dec 21
Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million. Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. Ankündigung • Dec 20
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer Bioxyne Limited announced joining of Mr. Sam Watson the board as Joint Chief Executive Officer. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 24
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million. Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million on October 24, 2022. The Direct Selling business comprises of Bioxyne International Pty Limited, Bioxyne International (NZ) Limited, Bioxyne International Sdn Bhd, PT Gamata Utama, Global Treasure New Zealand Limited and New Zealand Nutritional Research Limited. Ankündigung • Oct 04
Bioxyne Limited, Annual General Meeting, Oct 28, 2022 Bioxyne Limited, Annual General Meeting, Oct 28, 2022, at 14:00 AUS Eastern Standard Time. Reported Earnings • Oct 02
Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021) Full year 2022 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2021). Revenue: AU$2.48m (up 13% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021) Full year 2022 results: EPS: AU$0 (up from AU$0.001 loss in FY 2021). Revenue: AU$2.52m (up 14% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Jun 24
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Ankündigung • Jun 08
Bioxyne Limited Announces Board Changes Bioxyne Limited announced that Mr. Patrick Ford, after serving the company as a director for 17 years, including as chairman of thecompany between 2008 and 2012, has advised the board that Patrick will retire on 30 June 2022. Mr. Guy Robertson, company secretary, will be appointed an executive director, on 30 June 2022. Mr. Robertson is a chartered accountant and is currently a director of Hastings Technology Metals Ltd, Artemis Resources Limited, Metal Bank Limited and Greentech Metals Limited. Ms Rachel Qian, the group's financial controller, will be appointed assistant company secretary, with effectfrom 30 June 2022. Ms Qian has a B.Com, master of accounting (Macquarie), is CPA qualified and is member of the Governance Institute of Australia. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 24
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: AU$0 (up from AU$0.001 loss in 1H 2021). Revenue: AU$1.42m (up 13% from 1H 2021). Net income: AU$4.6k (up AU$289.2k from 1H 2021). Profit margin: 0.3% (up from net loss in 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 04
Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.20m (down 5.6% from FY 2020). Net loss: AU$495.7k (loss narrowed 16% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.22m (down 4.3% from FY 2020). Net loss: AU$425.7k (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 03
Full year earnings released - AU$0.00093 loss per share Over the last 12 months the company has reported total losses of AU$593.1k, with losses narrowing by 53% from the prior year. Total revenue was AU$2.32m over the last 12 months, up 5.4% from the prior year. 
